Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference Read more about Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering Read more about Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
Editas Medicine Announces Proposed Public Offering Read more about Editas Medicine Announces Proposed Public Offering
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress Read more about Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting Read more about Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences Read more about Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference Read more about Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Editas Medicine to Participate in Upcoming Investor Conferences Read more about Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 Read more about Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress Read more about Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
